Shorter radiation for prostate cancer? new trial tests Ultra-Fast schedule
NCT ID NCT05786742
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 35 times
Summary
This study is testing whether a shorter, more intense course of radiation (ultra-hypofractionation) is as safe and effective as the standard moderately hypofractionated schedule for men with localized prostate cancer. All participants also receive a brachytherapy boost. The trial will compare side effects, quality of life, and cancer control over 5 to 10 years. About 205 men with low- or intermediate-risk prostate cancer are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHUdeQuebec
RECRUITINGQuébec, G1R 2J6, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiation therapy (ultra-hypofractionated vs. moderately hypofractionated) with HDR brachytherapy boost
What this could lead to
If successful, this could offer a shorter, more convenient radiation schedule for prostate cancer without increasing side effects.
What could go wrong
This is an early-phase study (phase 1-2) with a small number of participants, so results may not apply to all patients. There is a risk that the shorter schedule could cause more side effects or be less effective at controlling cancer long-term.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.